The Alfalfa-inpatient-CAT assessment model: a thrombotic risk assessment model for inpatient cancer patients.
Cancer
Cancer-associated thrombosis
Inpatients
Risk assessment
Venous thromboembolism
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
30 Jul 2024
30 Jul 2024
Historique:
received:
13
03
2024
accepted:
23
07
2024
medline:
31
7
2024
pubmed:
31
7
2024
entrez:
30
7
2024
Statut:
epublish
Résumé
To construct a venous thromboembolism (VTE) risk assessment model specifically for inpatients with cancer. Patients were included according to the inclusion criteria. Univariate and multivariate analyses of all variables were included to develop a VTE risk assessment model applicable to the derivation cohort. Hosmer-Lemeshow test and receiver operating characteristic (ROC) curve were used to test the fit degree and identification validity of the model. The patient data from separate validation cohorts verified the external population. A total of 944 cancer patients were included in this study. Alfalfa-inpatient-CAT model, a risk assessment model for VTE in hospitalized cancer patients, was established, which mainly includes hypertension, surgical history (nearly one month), history of VTE, peripherally inserted central venous catheters (PICC), chemotherapy, PT < 12.85 s, D-dimer ≥ 1.805 μg/mL, hemoglobin ≤ 114.5 g/L, CRP ≥ 7.575 mg/L. Hosmer-Lemeshow test results showed P = 0.353 > 0.05, (χ This study developed a new VTE risk assessment model - Alfalfa-inpatient-CAT model - for hospitalized cancer patients at high risk of thrombosis. This model has a good fitting degree and discriminant validity. It is expected to provide some reference for the clinical treatment of inpatients with cancer through continuous optimization.
Identifiants
pubmed: 39080579
doi: 10.1186/s12885-024-12678-9
pii: 10.1186/s12885-024-12678-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
919Informations de copyright
© 2024. The Author(s).
Références
Kuperman A, López-Reyes R, Bosco LJ, et al. Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism. J Thromb Thrombolysis. 2018;45(3):360–8.
doi: 10.1007/s11239-018-1610-9
pubmed: 29383557
Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122(10):1712–23.
doi: 10.1182/blood-2013-04-460121
pubmed: 23908465
Mulder FI, Horváth-Puhó E, van Es N, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021;137(14):1959–69.
doi: 10.1182/blood.2020007338
pubmed: 33171494
Connolly GC, Khorana AA. Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Thromb Res. 2010;125 Suppl 2:S1–7.
doi: 10.1016/S0049-3848(10)00227-6
pubmed: 20433985
Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon. 2005;51(2–3):70–8.
doi: 10.1016/j.disamonth.2005.02.003
pubmed: 15900257
Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902–7.
doi: 10.1182/blood-2007-10-116327
pubmed: 18216292
pmcid: 2384124
Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010;8(11):2450–7.
doi: 10.1111/j.1538-7836.2010.04044.x
pubmed: 20738765
Mansfield AS, Tafur AJ, Wang CE, Kourelis TV, Wysokinska EM, Yang P. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer. J Thromb Haemost. 2016;14(9):1773–8.
doi: 10.1111/jth.13378
pubmed: 27273134
pmcid: 5035574
Rupa-Matysek J, Lembicz M, Rogowska EK, Gil L, Komarnicki M, Batura-Gabryel H. Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients. Med Oncol. 2018;35(5):63.
doi: 10.1007/s12032-018-1120-9
pubmed: 29616356
pmcid: 5882764
Francis CW. Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients. N Engl J Med. 2007;356(14):1438–44.
doi: 10.1056/NEJMcp067264
pubmed: 17409325
Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood. 2008;112(7):2703–8.
doi: 10.1182/blood-2008-02-142422
pubmed: 18539899
Piovella F, Wang CJ, Lu H, et al. Deep-vein thrombosis rates after major orthopedic surgery in Asia. An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography. J Thromb Haemost. 2005;3(12):2664–70.
doi: 10.1111/j.1538-7836.2005.01621.x
pubmed: 16359505
Hakkim A, Fuchs TA, Martinez NE, et al. Activation of the Raf-MEK-ERK pathway is required for neutrophil extracellular trap formation. Nat Chem Biol. 2011;7(2):75–7.
doi: 10.1038/nchembio.496
pubmed: 21170021
Yinping Z, Yan C, Zhihui Q, et al. Risk factors for picC-associated deep vein thrombosis in upper extremity in patients with lung cancer undergoing chemotherapy. Chin J Nurs. 2016;51(04):434–7.
Yuan H, Qian C, Huang Y. The relationship between hypertension and deep vein thrombosis in lower extremity. J Thromb Hemost. 2017;023(005):804–6.
Guo Y, Hu L, Wang M. Relationship between venous thrombosis and blood coagulation in patients with peripheral venous catheterization. Chin J Clin Oncol. 2019;26(11):1214–7.
Kanz R, Vukovich T, Vormittag R, et al. Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost. 2011;9(1):57–63.
doi: 10.1111/j.1538-7836.2010.04069.x
pubmed: 20874781
Musil D. Acute infections, venous thrombosis, and recommended thromboprophylaxis. Vnitr Lek. 2020;66(8):17–23 Winter, English.
doi: 10.36290/vnl.2020.153
pubmed: 33740855
Khorana AA, Connolly GC. Assessing risk of venous throm-boembolism in the patient with cancer. J Clin Oncol. 2009;27:4839–47.
doi: 10.1200/JCO.2009.22.3271
pubmed: 19720906
pmcid: 2764392
Horsted F, West J, Grainge MJ, et al. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 2012;9:e1001275.
doi: 10.1371/journal.pmed.1001275
pubmed: 22859911
pmcid: 3409130
Cronin-Fenton DP, Søndergaard F, Pedersen LA. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006. Br J Cancer. 2010;103:947.
doi: 10.1038/sj.bjc.6605883
pubmed: 20842120
pmcid: 2965880